Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Eluforsen: a potential new treatment option for people with cystic fibrosis (CF) due to the F508del gene mutation?

Eluforsen: a potential new treatment option for people with cystic fibrosis (CF) due to the F508del gene mutation?

Resource Type

CF Research News

Authors

Isabelle Sermet-Gaudelus, John P. Clancy, David P. Nichols, Jerry A. Nick, Kris De Boeck, George M. Solomon, Marcus A. Mall,h,i, James Bolognese, Florilene Bouisset, Wilhelmina den Hollander, Nicolas Paquette-Lamontagne, Nigel Tomkinson, Noreen Henig
J. Stuart Elborn and Steven M. Rowe

References

J Cyst Fibros. 2018 Nov 19. pii: S1569-1993(18)30914-7. doi: 10.1016/j.jcf.2018.10.015

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Antisense oligonucleotide [3]
Clinical trial [4]
Cystic Fibrosis Transmembrane Conductance Regulator delta F508 [5]
Nasal potential difference [6]
Pulmonary Medicine [7]

Date

Monday, November 19, 2018

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/eluforsen-potential-new-treatment-option-people-cystic-fibrosis-cf

Links
[1] https://www.ecfs.eu/sites/default/files/JCF-D-18-00230R2_FINAL_Elborn_061218.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/?term=Antisense%20oligonucleotide%20eluforsen [3] https://www.ecfs.eu/research-article-keywords/antisense-oligonucleotide [4] https://www.ecfs.eu/research-article-keywords/clinical-trial [5] https://www.ecfs.eu/research-article-keywords/cystic-fibrosis-transmembrane-conductance-regulator-delta-f508 [6] https://www.ecfs.eu/research-article-keywords/nasal-potential-difference [7] https://www.ecfs.eu/research-article-keywords/pulmonary-medicine [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines